Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 04/25/17 → 03/12/19 |
Funding
- Bayer Healthcare Pharmaceuticals Incorporated: $28,549.78
Phase II Trial to Study Efficacy Safety Pharmacokinetic & Pharmacodynamic Effects of the Oral Partial Adenosine A1 Receptor Agonist Neladenoson Bialanate over 20 weeks in Patients with Chronic Heart Failure with Reduced Ejection Fraction
- Skopicki, Hal A (PI)
- Lawson, William (CoPI)
- Bloom, Michelle (CoPI)
- Papadimitriou, Lampros (CoPI)
- Tallman, Mark (CoPI)
Project: Research